Novel Transcriptomic Signatures in Fibrostenotic Crohn’s Disease: Dysregulated Pathways, Promising Biomarkers, and Putative Therapeutic Targets
Animesh Acharjee(Cancer Research UK Clinical Trials Unit), Subrata Ghosh(University College Cork), Csilla Várnai(University of Birmingham), Sarah Akiror(University of Birmingham), Asma Amamou(Inserm), Gary Reynolds(Institut thématique Immunologie, inflammation, infectiologie et microbiologie), Louisa Jeffery(Institute of Immunology), Giovanni Santacroce(Università Cattolica del Sacro Cuore), Marietta Iacucci(University Hospitals Birmingham NHS Foundation Trust), Davide Zardo(Ospedale San Bortolo), Georgios V. Gkoutos(University Hospitals Birmingham NHS Foundation Trust), Uday N. Shivaji(National Institute for Health and Care Research)
Cited by 8
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters
|Cell|2016|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558